Advocate General Ćapeta concludes that it is not clear to Novo Nordisk that the payment obligation is a tax and cannot be considered a price reduction. All requirements for the payment to be treated as a price reduction have been met. However, the AG notes that a Member State can adopt a more explicit tax measure to achieve the objective of financing national public health policy.
Source
See also
- See also
- Join the Linkedin Group on Global E-Invoicing/E-Reporting/SAF-T Developments, click HERE
